AveXis Inc (AVXS) Insider Brian K. Kaspar Sells 15,000 Shares
AveXis Inc (NASDAQ:AVXS) insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $118.07, for a total transaction of $1,771,050.00. Following the transaction, the insider now directly owns 1,792,147 shares in the company, valued at $211,598,796.29. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of AveXis Inc (NASDAQ AVXS) opened at $115.14 on Wednesday. The firm has a market cap of $3,680.00 and a PE ratio of -20.63. AveXis Inc has a fifty-two week low of $53.94 and a fifty-two week high of $128.00.
AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter last year, the firm earned ($0.87) EPS. analysts predict that AveXis Inc will post -6.23 earnings per share for the current fiscal year.
Several research analysts have issued reports on the stock. William Blair reissued a “buy” rating on shares of AveXis in a research report on Tuesday, January 30th. BMO Capital Markets reissued a “buy” rating and set a $150.00 price objective on shares of AveXis in a research report on Thursday, January 18th. Credit Suisse Group assumed coverage on shares of AveXis in a research report on Wednesday, January 17th. They set an “outperform” rating and a $134.00 price objective on the stock. Royal Bank of Canada reissued a “hold” rating and set a $92.00 price objective on shares of AveXis in a research report on Tuesday, January 9th. Finally, Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the stock. AveXis currently has a consensus rating of “Buy” and a consensus price target of $113.89.
WARNING: “AveXis Inc (AVXS) Insider Brian K. Kaspar Sells 15,000 Shares” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/02/07/avexis-inc-avxs-insider-brian-k-kaspar-sells-15000-shares-2.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.